DrugPatentWatch Database Preview
CARBOPLATIN Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Carboplatin, and when can generic versions of Carboplatin launch?
Carboplatin is a drug marketed by Cipla Ltd, Fresenius Kabi Usa, Hospira, Mylan Labs Ltd, Pliva, Sandoz, Watson Labs Teva, West-ward Pharms Int, Accord Hlthcare, Actavis Totowa, Akorn, Eugia Pharma, Fresenius Kabi Oncol, Gland Pharma Ltd, Ingenus Pharms Llc, Mylan Institutional, Nanjing King-friend, Pharmachemie Bv, Pliva Lachema, Sandoz Inc, Sun Pharma Global, Teva Parenteral, and Teva Pharms Usa. and is included in thirty-three NDAs.
The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Twelve suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the carboplatin profile page.
Summary for CARBOPLATIN
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 33 |
| Suppliers / Packagers: | 12 |
| Bulk Api Vendors: | 80 |
| Clinical Trials: | 1,942 |
| Patent Applications: | 181 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CARBOPLATIN |
| DailyMed Link: | CARBOPLATIN at DailyMed |
Pharmacology for CARBOPLATIN
| Ingredient-type | Platinum-containing Compounds |
| Drug Class | Platinum-based Drug |
Medical Subject Heading (MeSH) Categories for CARBOPLATIN
Synonyms for CARBOPLATIN
| (SP-4-2)-Diamimine[1,1-cyclobutanedi(carboxylato-kO)(2-)]platinum |
| (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum |
| 1,1-Cyclobutanedicarboxylate |
| 1,1-Cyclobutanedicarboxylate diammine platinum (II) |
| 1,1-Cyclobutanedicarboxylate diammine platinum(II) |
| 1,1-CYCLOBUTANEDICARBOXYLATODIAMMINE PLATINUM |
| 1,1-Cyclobutanedicarboxylatodiammineplatinum |
| 1,1-Cyclobutanedicarboxylatodiammineplatinum (II) |
| 1,1-Cyclobutanedicarboxylatodiammineplatinum(II) |
| 10329-EP2269988A2 |
| 10329-EP2269989A1 |
| 10329-EP2270008A1 |
| 10329-EP2272827A1 |
| 10329-EP2275102A1 |
| 10329-EP2275412A1 |
| 10329-EP2275413A1 |
| 10329-EP2275420A1 |
| 10329-EP2277876A1 |
| 10329-EP2280012A2 |
| 10329-EP2281815A1 |
| 10329-EP2287156A1 |
| 10329-EP2292233A2 |
| 10329-EP2292614A1 |
| 10329-EP2292615A1 |
| 10329-EP2292617A1 |
| 10329-EP2295055A2 |
| 10329-EP2295416A2 |
| 10329-EP2295426A1 |
| 10329-EP2295427A1 |
| 10329-EP2298748A2 |
| 10329-EP2298764A1 |
| 10329-EP2298765A1 |
| 10329-EP2298768A1 |
| 10329-EP2298772A1 |
| 10329-EP2298778A1 |
| 10329-EP2301536A1 |
| 10329-EP2301538A1 |
| 10329-EP2301928A1 |
| 10329-EP2301933A1 |
| 10329-EP2305243A1 |
| 10329-EP2305640A2 |
| 10329-EP2305642A2 |
| 10329-EP2305671A1 |
| 10329-EP2308812A2 |
| 10329-EP2308833A2 |
| 10329-EP2308839A1 |
| 10329-EP2308855A1 |
| 10329-EP2308861A1 |
| 10329-EP2311453A1 |
| 10329-EP2311455A1 |
| 10329-EP2311807A1 |
| 10329-EP2311808A1 |
| 10329-EP2311825A1 |
| 10329-EP2311827A1 |
| 10329-EP2311829A1 |
| 10329-EP2311840A1 |
| 10329-EP2314590A1 |
| 10329-EP2316452A1 |
| 10329-EP2316831A1 |
| 10329-EP2316832A1 |
| 10329-EP2316833A1 |
| 10329-EP2316834A1 |
| 10329-EP2374454A1 |
| 41575-94-4 |
| 575C944 |
| 6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione |
| 6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione diamine |
| 7,7-diamino-[?]spiro[3.5]nonane-5,9-dione |
| 7,7-dimethyl-6,8-dioxa-7$l^{4}-platinaspiro[3.5]nonane-5,9-dione |
| 70903-55-8 |
| AB0013326 |
| AB01273939-01 |
| AB01274771_03 |
| AB01274771-01 |
| AB01274771-02 |
| AB01568249_01 |
| AC-1457 |
| AC1L1DYT |
| AC1L20N7 |
| AC1NR9YB |
| AC1O7G18 |
| AK136131 |
| AKOS015905301 |
| AKOS022185820 |
| AKOS024457202 |
| Ambap41575-94-4 |
| AN-265 |
| AOB5507 |
| AS-13313 |
| azane; cyclobutane-1,1-dicarboxylic acid; platinum |
| BC204693 |
| BDBM50274681 |
| BDBM92389 |
| BG3F62OND5 |
| BSPBio_003145 |
| C 2538 |
| C-21145 |
| C6H10N2O4Pt |
| C6H6O4Pt.2NH3 |
| Carbopaltin |
| Carboplatin (JAN/USP/INN) |
| Carboplatin (JP17/USP/INN) |
| Carboplatin (USAN) |
| Carboplatin [USAN:INN:BAN:JAN] |
| Carboplatin [USAN:USP:INN:BAN:JAN] |
| Carboplatin, British Pharmacopoeia (BP) Reference Standard |
| Carboplatin, United States Pharmacopeia (USP) Reference Standard |
| Carboplatine |
| Carboplatine [French] |
| Carboplatino |
| Carboplatino [Spanish] |
| Carboplatinum |
| Carboplatinum [Latin] |
| Caronplatin, 4 |
| CAS-41575-94-4 |
| Cbdca |
| cbdca(2-) |
| CCG-204325 |
| CCG-39887 |
| CCRIS 3404 |
| CHEBI:31355 |
| CHEBI:35690 |
| cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum |
| cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) |
| cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) |
| cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) |
| cis-Diammine(1,1-cyclobutanedicarboxylato) platinum |
| cis-Diammine(1,1-cyclobutanedicarboxylato)platinum |
| cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) |
| cis-Diammine(cyclobutanedicarboxylato)platinum II |
| Cis-Diammine(cyclobutanedicarboxylato)platinumII |
| cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum |
| cis-diamminecyclobutanedicarboxylatoplatinum(II); |
| CS-1121 |
| CTK7I5753 |
| cyclobutane dicarboxylate platinum (ii) |
| cyclobutane-1,1-dicarboxylate |
| cyclobutane-1,1-dicarboxylate(2-) |
| cyclobutane-1,1-dicarboxylic acid- platinum(1:1) |
| cyclobutane-1,1-dicarboxylic acid; platinum |
| D01363 |
| D0X7HM |
| DB00958 |
| diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum |
| Diammine-1,1-cyclobutane dicarboxylate platinum II |
| Diammine(1,1-cyclobutanedicarboxylato)platinum (II) |
| Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum |
| diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum |
| DivK1c_000892 |
| DR002048 |
| DSSTox_CID_26742 |
| DSSTox_GSID_46742 |
| DSSTox_RID_81870 |
| DTXSID3046742 |
| DVQHYTBCTGYNNN-UHFFFAOYSA-N |
| EBD50809 |
| EINECS 255-446-0 |
| Epitope ID:194801 |
| Ercar |
| EU-0100230 |
| FT-0602925 |
| H876 |
| HMS1921J16 |
| HMS2090M05 |
| HMS2092B22 |
| HMS3260N21 |
| HMS3269H03 |
| HMS502M14 |
| HSDB 6957 |
| HY-17393 |
| I14-2390 |
| IDI1_000892 |
| IUPAC: Azane |
| JM 8 |
| JM-8 |
| K-8751 |
| KBio1_000892 |
| KBio2_002009 |
| KBio2_004577 |
| KBio2_007145 |
| KBio3_002645 |
| KBioGR_000713 |
| KBioSS_002009 |
| Lopac-C-2538 |
| Lopac0_000230 |
| LP00230 |
| LS-117689 |
| MFCD00070464 |
| MolPort-003-845-609 |
| MolPort-006-147-683 |
| MolPort-035-395-692 |
| NCGC00015223-01 |
| NCGC00015223-02 |
| NCGC00015223-03 |
| NCGC00015223-04 |
| NCGC00015223-05 |
| NCGC00015223-06 |
| NCGC00015223-07 |
| NCGC00015223-08 |
| NCGC00015223-09 |
| NCGC00015223-10 |
| NCGC00093695-01 |
| NCGC00094961-01 |
| NCGC00094961-02 |
| NCGC00094961-03 |
| NCGC00162099-01 |
| NCGC00162099-02 |
| NCGC00167800-01 |
| NCGC00178242-01 |
| NCGC00260915-01 |
| NCGC00263858-02 |
| NCGC00263858-03 |
| NINDS_000892 |
| NSC 201345 |
| NSC 241240 |
| NSC-201345 |
| NSC-241240 |
| NSC-758182 |
| NSC201345 |
| NSC241240 |
| NSC758182 |
| OLESAACUTLOWQZ-UHFFFAOYSA-L |
| Paraplatin |
| Paraplatin (Bristol Meyers) |
| Paraplatin (TN) |
| Paraplatin-AQ |
| Paraplatin, Carboplatin |
| Pharmakon1600-01502106 |
| Platinum, {diammine[1,1-cyclobut |
| Platinum, {diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-,} (SP-4-2)- |
| Platinum, diamine(1, 1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)- |
| Platinum, diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))-, (SP-4-2)- |
| Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) |
| Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)- |
| Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)- |
| Platinum, diammine[1,1-cyclobutanedi(carboxylato-.kappa.O)(2-)]-, (SP-4-2)- |
| Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)- |
| Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)- |
| Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)- |
| Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)- |
| platinum(+2) cation |
| Platinum(II), (1, 1-cyclobutanedicar |
| Platinum(II), (1, 1-cyclobutanedicarboxylato)diammine-, cis- |
| Platinum(II), (1,1-cyclobutanedicarboxylato)diammine-, cis- |
| Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis- |
| RL03611 |
| s1215 |
| SBI-0050218.P002 |
| SC-18620 |
| SCHEMBL2671349 |
| SCHEMBL4964 |
| SPBio_000716 |
| Spectrum_001529 |
| SPECTRUM1502106 |
| Spectrum2_000898 |
| Spectrum3_001503 |
| Spectrum4_000337 |
| Spectrum5_001094 |
| SR-01000076253 |
| SR-01000076253-5 |
| ST24046284 |
| STL451040 |
| Tox21_112586 |
| Tox21_112586_1 |
| Tox21_500230 |
| UNII-BG3F62OND5 |
| W-106301 |
| ZB013490 |
US Patents and Regulatory Information for CARBOPLATIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 091063-003 | Nov 9, 2011 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Teva Pharms Usa | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 077139-004 | Sep 21, 2005 | AP | RX | No | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Eugia Pharma | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 205487-001 | Mar 28, 2016 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Actavis Totowa | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 078732-004 | Feb 6, 2012 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pliva Lachema | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 078631-002 | Dec 2, 2008 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Fresenius Kabi Usa | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 077247-002 | Oct 21, 2004 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Hospira | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 076517-003 | Oct 14, 2004 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
